Muna Bhanji sold $2,642 of NTLA
director at Intellia Therapeutics, Inc.. 265 shares at an average of $9.97, traded Jan 29, 2025, filed Jan 31, 2025.
Score components
- +15RoleDirector
- 0Trade size$3k at market
- 0Share of holdings soldSold 1.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.2%, 3m -14.3%, 6m +11.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-011757, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2025 | SOpen-market sale Common Stock10b5-1 | -265 | $9.97 | $2,642 | 19,468 | Jan 31, 2025 |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $23k 1,864 shares | -3% | |
| 19Weak | Intellia Therapeutics, Inc. | John M Leonard President and CEO | $287k 22,675 shares | -2% | |
| 31Weak | NTLAsell Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $91k 8,111 shares | -5% | |
| 29Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $44k 2,641 shares | -4% | |
| 19Weak | Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $84k 4,677 shares | -3% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $17k 1,211 shares | -1% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $8,364 607 shares | -1% | |
| 40Moderate | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $96k 10,397 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $88k 9,515 shares | -10% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | Fred E Cohen director | $1.4M 150,000 shares | +261% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.